ArticleCurrent oncology (Toronto, Ont.)2021
Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study.
Article in Current oncology (Toronto, Ont.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.Frontiers in immunology · 2026Pooled it
- Ovarian Lymphoma and Bone Metastasis Presenting With Paraparesis in an Adolescent: A Case Report.The American journal of case reports · 2026Article
- Interpretable deep learning radiomics fromBMC medical imaging · 2026Article
- Prognostic Value of the CALLY Index in Diffuse Large B-Cell Lymphoma: Linking Inflammation, Nutrition, and Tumor Biology.Cancers · 2026Article
- Therapeutic efficacy monitoring in canine lymphoma patients via quantifying CDC6 plasma levels.BMC veterinary research · 2026Article
- Article
- Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma.Cancer medicine · 2025Article
- Clinical characteristics and prognosis of ventricular primary central nervous system lymphoma: a case series and literature review.Chinese neurosurgical journal · 2025Article
- Correlations Between Immunophenotypic Markers and Clinical Progression in Romanian Patients Diagnosed with Diffuse Large B-Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Preoperative multiparameter MRI-based prediction of Ki-67 expression in primary central nervous system lymphoma.Precision radiation oncology · 2025Article
- Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2.Frontiers in immunology · 2025Article
- Baseline PET/CT metabolic parameters in the double-expressor subtype of diffuse large B-cell lymphoma: development of a clinical-radiologic-pathologic predictive model.Frontiers in oncology · 2025Article
- Clinicopathological and genetic analyses of thyroid large B-cell lymphoma in a Japanese population.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Prognostic value ofQuantitative imaging in medicine and surgery · 2024Article
- Aligning outcomes: DLBCL prognosis at a 4th Level University Hospital in Bogotá is comparable to high-income nations, identification of additional prognostic markers for overall survival and relapse.Ecancermedicalscience · 2024Article
- Comparison of Ki67 Proliferation Index in Gastrointestinal Non-Hodgkin Large B-Cell Lymphomas: The Conventional Method of Evaluation or AI Evaluation?Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and prognostic information is essential in finding the right treatment. This study evaluated the prognostic significance of Ki-67 in patients with DLBCL.
methodsPatients with DLBCL, treated with first-line R-CHOP, were retrospectively analyzed in groups of high (>70%) and low (≤70%) Ki-67. Parameters of interest were the international prognostic index (IPI), treatment response, progression-free survival (PFS) and overall survival (OS). A chi-squared test or Fisher's exact test was conducted to analyze categorical variables. Kaplan-Meier and log-rank tests were applied for survival analyses. Finally, a multivariate linear regression analysis was performed, including gender, Ki-67 ≤ 70% or >70%, IPI and presence of B symptoms.
resultsOverall, 58 patients were included. No significant association was found between Ki-67 status and IPI (
conclusionFuture studies with larger patient cohorts are needed in order to elucidate the prognostic role of Ki-67 in patients with DLBCL treated with R-CHOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.